Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Sertralin ratiopharm

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Sertralin Testmiljö

Sertralin

Klass : 2

  1. Eleftheriou G, Zandonella Callegher R, Butera R, De Santis M, Cavaliere AF, Vecchio S et al. Consensus Panel Recommendations for the Pharmacological Management of Pregnant Women with Depressive Disorders. Int J Environ Res Public Health. 2023;20(16):6565.
  2. Gao SY, Wu QJ, Sun C, Zhang TN, Shen ZQ, Liu CX et al. Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births. BMC Med. 2018;16(1):205.
  3. Jordan S, Morris JK, Davies GI, Tucker D, Thayer DS, Luteijn JM et al. Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants in Pregnancy and Congenital Anomalies: Analysis of Linked Databases in Wales, Norway and Funen, Denmark. PLoS One. 2016;11(12):e0165122.
  4. Wang S, Yang L, Wang L, Gao L, Xu B, Xiong Y. Selective Serotonin Reuptake Inhibitors (SSRIs) and the Risk of Congenital Heart Defects: A Meta-Analysis of Prospective Cohort Studies. J Am Heart Assoc. 2015;4(5):1–7
  5. Furu K, Kieler H, Haglund B, Engeland A, Selmer R, Stephansson O et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ. 2015;350:h1798.
  6. Ban L, Gibson JE, West J, Fiaschi L, Sokal R, Smeeth L et al. Maternal depression, antidepressant prescriptions, and congenital anomaly risk in offspring: a population-based cohort study. BJOG. 2014;121(12):1471-81.
  7. Kolding L, Ehrenstein V, Pedersen L, Sandager P, Petersen OB, Uldbjerg N,Pedersen LH. Antidepressant use in pregnancy and severe cardiac malformations: Danish register-based study. BJOG. 2021 Nov;128(12):1949-1957.
  8. Jimenez-Solem E, Andersen JT, Petersen M, Broedbaek K, Jensen JK, Afzal S et al. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open. 2012;2(3):.
  9. Grigoriadis S, VonderPorten EH, Mamisashvili L, Roerecke M, Rehm J, Dennis CL et al. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry. 2013;74:e293-308.
  10. Wemakor A, Casson K, Garne E, Bakker M, Addor MC, Arriola L et al. Selective serotonin reuptake inhibitor antidepressant use in first trimester pregnancy and risk of specific congenital anomalies: a European register-based study. Eur J Epidemiol. 2015;30(11):1187-98.
  11. Myles N, Newall H, Ward H, Large M. Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations. Aust N Z J Psychiatry. 2013;47(11):1002-12.
  12. Bérard A, Iessa N, Chaabane S, Muanda FT, Boukhris T, Zhao JP. The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;81:589-604.
  13. Källén B, Borg N, Reis M. The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel). 2013;6:1221-86.
  14. Williams M, Wooltorton E. Paroxetine (Paxil) and congenital malformations. Canad Med Assoc J. 2005;173:1320-1.
  15. Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med. 2010;40(10):1723-33.
  16. Wisner KL, Oberlander TF, Huybrechts KF. The Association Between Antidepressant Exposure and Birth Defects-Are We There Yet?. JAMA Psychiatry. 2020;77(12):1215-1216.
  17. Petersen I, Evans SJ, Gilbert R, Marston L, Nazareth I. Selective serotonin reuptake inhibitors and congenital heart anomalies: comparative cohort studies of women treated before and during pregnancy and their children. J Clin Psychiatry. 2016;77(1):e36-42.
  18. Rommel AS, Momen NC, Molenaar NM, Agerbo E, Bergink V, Munk-Olsen T et al. Antidepressant use during pregnancy and risk of adverse neonatal outcomes: A comprehensive investigation of previously identified associations. Acta Psychiatr Scand. 2022;145(6):544-556.
  19. Kautzky A, Slamanig R, Unger A, Höflich A. Neonatal outcome and adaption after in utero exposure to antidepressants: A systematic review and meta-analysis. Acta Psychiatr Scand. 2022;145(1):6-28.
  20. Nörby U, Forsberg L, Wide K, Sjörs G, Winbladh B, Källén K. Neonatal Morbidity After Maternal Use of Antidepressant Drugs During Pregnancy. Pediatrics. 2016;138:.
  21. Malm H, Sourander A, Gissler M, Gyllenberg D, Hinkka-Yli-Salomäki S, McKeague IW et al. Pregnancy Complications Following Prenatal Exposure to SSRIs or Maternal Psychiatric Disorders: Results From Population-Based National Register Data. Am J Psychiatry. 2015;172(12):1224-32.
  22. Forsberg L, Navér L, Gustafsson LL, Wide K. Neonatal adaptation in infants prenatally exposed to antidepressants- clinical monitoring using neonatal abstinence score. PLoS One. 2014;9:e111327.
  23. Huybrechts KF, Bateman BT, Palmsten K, Desai RJ, Patorno E, Gopalakrishnan C et al. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA. 2015;313(21):2142-51.
  24. Ng QX, Venkatanarayanan N, Ho CYX, Sim WS, Lim DY, Yeo WS. Selective Serotonin Reuptake Inhibitors and Persistent Pulmonary Hypertension of the Newborn: An Update Meta-Analysis. J Womens Health (Larchmt). 2019;28(3):331-338.
  25. EMA. PRAC recommendations on signals adopted at the 28 Sep-1 Oct 2020 PRAC meeting. EMA [www]. [updated 2020-10-26, cited 2024-04-10].
  26. Sujan AC, Rickert ME, Öberg AS, Quinn PD, Hernández-Díaz S, Almqvist C et al. Associations of Maternal Antidepressant Use During the First Trimester of Pregnancy With Preterm Birth, Small for Gestational Age, Autism Spectrum Disorder, and Attention-Deficit/Hyperactivity Disorder in Offspring. JAMA. 2017;317(15):1553-1562.
  27. Brown HK, Ray JG, Wilton AS, Lunsky Y, Gomes T, Vigod SN. Association Between Serotonergic Antidepressant Use During Pregnancy and Autism Spectrum Disorder in Children. JAMA. 2017;317(15):1544-1552.
  28. Rai D, Lee BK, Dalman C, Newschaffer C, Lewis G, Magnusson C. Antidepressants during pregnancy and autism in offspring: population based cohort study. BMJ. 2017;358:j2811.